X4 Pharmaceuticals (XFOR) Q4 2024 Annual Earnings
XFOR·Reported March 25, 2025·Before market open
X4 Pharmaceuticals reported Q4 2024 revenue of $1.4M, missed analyst consensus of $2.2M by $800.2K. Diluted EPS came in at $-6.01, missed the $-5.11 consensus by $0.90.
Revenue
$1.4Mmissed by $800.2K
Consensus: $2.2MDiluted EPS
$-6.01missed by $0.90
Consensus: $-5.11
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about X4 Pharmaceuticals's Q4 2024 earnings report.
X4 Pharmaceuticals (XFOR) reported Q4 2024 earnings on March 25, 2025 before market open.
X4 Pharmaceuticals reported revenue of $1.4M and diluted EPS of $-6.01 for Q4 2024.
Revenue missed the consensus estimate of $2.2M by $800.2K. EPS missed the consensus estimate of $-5.11 by $0.90.
You can read the 10-K periodic report (0001628280-25-014805) directly on SEC EDGAR. The filing index links above go to sec.gov.